Our nutrition planning methodology is protected by a European patent, built on seven years of original research and validation across more than 10 million health assessments. Competitors can copy how a product looks. They cannot use the methodology behind it. That is not a feature advantage. It is a structural one.
We operate in 100+ markets with real local presence: certified nutritionists working in local languages, programmes adapted to each market and institutional relationships built country by country. That depth is slow and expensive to build, but it is why our outcomes remain consistent across markets and why the model is difficult to replicate quickly.
Nutrameg’s official medical institution status places us in a different legal and professional category from consumer health brands. It opens doors to public health partnerships, clinical care pathways and healthcare professional referrals. It also creates a compliance advantage, because the standards required of a medical institution are genuinely hard to replicate.
Every client who follows a Nutrameg programme strengthens our research dataset. More data improves personalisation, stronger personalisation improves outcomes, and better outcomes drive retention. That loop compounds over time, widening the gap between our methodology and what a newer entrant could build.
The hardest foundations are already in place: the methodology, medical institution status, patent protection, local presence in 100+ markets and public health relationships. The next chapter is scaling what already works by deepening existing markets, launching the clinical platform for healthcare institutions and entering new geographies only where proper localisation can be built.
Nutrameg is actively open to investment. We are not raising because the business cannot sustain itself. We are raising because there are two specific opportunities in front of us that capital can accelerate, and we want the right partners alongside us for them.
RESEARCH & DEVELOPMENT
Our patented nutrition planning methodology sits at the centre of Nutrameg and continues to improve as our dataset and research programme grow. Investment in R&D accelerates that progress and supports the clinical platform that will bring our methodology into formal collaboration with hospitals, clinics and healthcare providers.
GEOGRAPHIC EXPANSION
Nutrameg already operates in 100+ markets, but presence and depth are not the same. The near-term opportunity is to grow further within existing markets before prioritising new entry. Beyond that, we will expand into geographies where demand is clear and genuine localisation can be built properly.
The global nutrition and metabolic health market is one of healthcare's largest opportunities. Nutrameg operates in a still early segment: clinically validated, personalised nutrition programmes built for scale.
The driver is not a trend, but a structural gap between what nutrition science can now deliver and what healthcare systems currently provide. Closing that gap is increasingly necessary, and now technically possible.
Obesity, metabolic disease and diet-related conditions are placing growing pressure on healthcare systems. Early nutritional intervention can reduce that burden, giving healthcare providers a clear reason to fund effective programmes.
Personalised nutrition has strong clinical evidence behind it. What has been missing is the ability to deliver it at scale with the right credentials, localisation and clinical relationships. Nutrameg has built that.
Our public health partnerships show that healthcare systems are actively looking to integrate evidence-based nutrition into care pathways. Nutrameg is positioned to meet that need.
Personalised nutrition used to mean private dietitians: expensive, slow and limited to those who could afford it. Nutrameg makes clinical-grade support available through a smartphone, at a fraction of the cost.
Our investor deck covers the full commercial picture, including financial information that we do not publish publicly. All materials are distributed under a standard NDA, which we send alongside the deck.
We review every request personally. If there is a mutual fit, we will follow up within five business days to arrange a briefing call with the relevant member of our leadership team.
If you prefer to reach out directly rather than through this form, contact details are found in the contact page.
For financial results, Board Meeting materials, investor enquiries, and analyst meetings
ir@nutrameg.comFor media enquiries, press releases, and media relations
press@nutrameg.comFor academic collaborations, clinical trial enquiries, and institutional access to our research platform
research@nutrameg.comFor health system integrations, government programmes, and enterprise licensing
enterprise@nutrameg.com
.svg)